19d agoSEC 8-KNEUTRAL 50General
IONIS PHARMACEUTICALS INC (IONS) files 8-K
Filed: 2026-07-10 AccNo: 0001140361-26-028154 Size: 155 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Archived explainer. For the current picture see today's IONS page.
Why Is IONIS PHARMACEUTICAL (IONS) Stock Down Today?
By the Top Tier Newswire AI Desk · July 11, 2026 at 9:16 AM ET · reviewed against 5 wire stories
IONIS PHARMACEUTICAL (IONS) is down -9.37% in the latest session. Our newswire has captured 5 stories on IONS across 4 sources in the last 36 hours, with AI sentiment reading bearish (avg 42/100).
IONIS PHARMACEUTICAL stock is down nearly 9.4% in the current session trading at $58.25. The decline follows news that Roche has discontinued two experimental Huntington’s disease therapies developed in partnership with the company according to Seeking Alpha. This move has contributed to continued downward pressure on the stock.
Earlier in the week the company’s shares dropped more than 20% after its Phase-3 CARDIO-TTRansform trial failed to meet its primary endpoint prompting a shareholder investigation notice from SueWallSt. Meanwhile IONIS PHARMACEUTICALS INC filed an 8-K with the SEC disclosing Regulation FD information and financial documents. The company also reaffirmed its 2026 financial guidance with no changes to its projections as reported by TipRanks and Seeking Alpha.
Despite the negative developments the company’s guidance for the fiscal year remains stable. However the ongoing setbacks in clinical trials and partnership decisions have weighed on investor sentiment. The average AI sentiment across five recent stories is 42 out of 100 indicating a generally negative tone across the coverage.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.
IONS by the numbers
Last: $58.25Session: -9.37%7 sessions: -24.96%Coverage: 5 stories / 4 sourcesAI sentiment: 42/100 (bearish)
The headlines behind the move
19d agoSeeking AlphaBEARISH 28General
Ionis extends losses as Roche scraps two partnered studies
Ionis Pharmaceuticals (IONS) stock falls as Roche (RHHBY) discontinues two experimental therapies for Huntington’s disease developed with the company. Read more here.
19d agoPR NewswireBEARISH 28General
IONS SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Ionis Pharmaceuticals
Ionis Pharmaceuticals lost more than 20% before the market opened -- a decline of nearly $17 -- after its Phase-3 CARDIO-TTRansform trial missed its primary endpoint. SueWallSt notifies investors of a pending investigation into potential securities law violations on behalf of IONS...
19d agoTipRanksBULLISH 56General
Ionis Pharmaceuticals Reaffirms 2026 Financial Guidance Outlook
The latest update is out from Ionis Pharmaceuticals ( ($IONS) ). Ionis Pharmaceuticals reaffirmed its previously announced financial guidance for the fiscal year en...
19d agoSeeking AlphaNEUTRAL 50General
Ionis Pharmaceuticals reiterates FY26 outlook, unchanged from April projections
Ionis Pharmaceuticals (IONS) has reiterated its previously issued financial outlook for the full fiscal year ending December 31, 2026. The corporate guidance remains entirely unchanged from the financial projections originally provided by the company on
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on IONS: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier IONS move explainers: 2026-07-23 · 2026-07-22 · 2026-07-13 · 2026-07-11